Igm Biosciences Stock Cash And Equivalents
| IGMS Stock | USD 10.43 0.97 10.25% |
IGM Biosciences fundamentals help investors to digest information that contributes to IGM Biosciences' financial success or failures. It also enables traders to predict the movement of IGM Stock. The fundamental analysis module provides a way to measure IGM Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to IGM Biosciences stock.
IGM | Cash And Equivalents |
IGM Biosciences Company Cash And Equivalents Analysis
IGM Biosciences' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current IGM Biosciences Cash And Equivalents | 469.14 M |
Most of IGM Biosciences' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, IGM Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
IGM Cash And Equivalents Driver Correlations
Understanding the fundamental principles of building solid financial models for IGM Biosciences is extremely important. It helps to project a fair market value of IGM Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since IGM Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of IGM Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of IGM Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
IGM Cash And Cash Equivalents Changes
Cash And Cash Equivalents Changes |
|
In accordance with the recently published financial statements, IGM Biosciences has 469.14 M in Cash And Equivalents. This is 42.85% lower than that of the Biotechnology sector and 4.93% higher than that of the Health Care industry. The cash and equivalents for all United States stocks is 82.64% higher than that of the company.
IGM Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses IGM Biosciences' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of IGM Biosciences could also be used in its relative valuation, which is a method of valuing IGM Biosciences by comparing valuation metrics of similar companies.IGM Biosciences is currently under evaluation in cash and equivalents category among its peers.
IGM Biosciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of IGM Biosciences from analyzing IGM Biosciences' financial statements. These drivers represent accounts that assess IGM Biosciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of IGM Biosciences' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 343.3M | 2.7B | 982.0M | 706.7M | 434.7M | 594.6M | |
| Enterprise Value | 322.1M | 2.5B | 877.4M | 626.6M | 362.7M | 537.0M |
IGM Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, IGM Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to IGM Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
IGM Fundamentals
| Return On Equity | -1.32 | ||||
| Return On Asset | -0.37 | ||||
| Operating Margin | (124.78) % | ||||
| Current Valuation | 389.6 M | ||||
| Shares Outstanding | 34.08 M | ||||
| Shares Owned By Insiders | 35.04 % | ||||
| Shares Owned By Institutions | 63.98 % | ||||
| Number Of Shares Shorted | 2.84 M | ||||
| Price To Earning | (7.72) X | ||||
| Price To Book | 7.13 X | ||||
| Price To Sales | 212.55 X | ||||
| Revenue | 2.13 M | ||||
| Gross Profit | 1.07 M | ||||
| EBITDA | (253.36 M) | ||||
| Net Income | (246.42 M) | ||||
| Cash And Equivalents | 469.14 M | ||||
| Cash Per Share | 10.95 X | ||||
| Total Debt | 40.51 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 10.79 X | ||||
| Book Value Per Share | 1.33 X | ||||
| Cash Flow From Operations | (192.23 M) | ||||
| Short Ratio | 11.97 X | ||||
| Earnings Per Share | (3.61) X | ||||
| Target Price | 19.6 | ||||
| Number Of Employees | 198 | ||||
| Beta | 0.19 | ||||
| Market Capitalization | 620.21 M | ||||
| Total Asset | 423.41 M | ||||
| Retained Earnings | (821.24 M) | ||||
| Working Capital | 305.12 M | ||||
| Current Asset | 1.23 M | ||||
| Current Liabilities | 3.37 M | ||||
| Net Asset | 423.41 M |
About IGM Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze IGM Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of IGM Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of IGM Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for IGM Stock Analysis
When running IGM Biosciences' price analysis, check to measure IGM Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IGM Biosciences is operating at the current time. Most of IGM Biosciences' value examination focuses on studying past and present price action to predict the probability of IGM Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IGM Biosciences' price. Additionally, you may evaluate how the addition of IGM Biosciences to your portfolios can decrease your overall portfolio volatility.